Juan Rivera
Miami Beach, FLNPI 1518012616
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,000 of the $37,077 with a category attached, or 94.4%. Johnson & Johnson accounts for 94.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $35,293 and has fallen 98.0% since, to $717 in 2025.
Across 73 payments — averaging $507.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$35K
- Novo Nordisk$520
- Stryker$491
- Pfizer$241
- Novartis$192
- Amarin Pharma, Inc.$112
- plus $521 from 14 others
What the payments were for
- Consulting fees$35,00094%
- Travel & lodging$4911%
- Food & beverage$1,5864%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $35,000 |
| Novo Nordisk | 28 | $520 |
| Stryker | 1 | $491 |
| Pfizer | 10 | $241 |
| Novartis | 7 | $192 |
| Amarin Pharma, Inc. | 6 | $112 |
| Merck | 1 | $109 |
| Boehringer Ingelheim | 4 | $93 |
| Abbott | 2 | $73 |
| Bayer | 2 | $40 |
| Amgen(2 entities) | 2 | $37 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Mimedx Group, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$35,000
- VARIAX$491
- ORTHOLOC 2 LAPIFUSE$491
- SIVEXTRO$109
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $16,307 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,613 |
| Atorvastatin Calcium | 67 | $1,324 |
| Amlodipine Besylate | 40 | $557 |
| Levothyroxine Sodium | 13 | $510 |
| Ezetimibe | 12 | $472 |
| Lisinopril | 41 | $460 |
| Metoprolol Succinate | 22 | $430 |
| Rosuvastatin Calcium | 27 | $424 |
| Chlorthalidone | 14 | $364 |
| Escitalopram Oxalate | 15 | $302 |
| Losartan Potassium | 17 | $292 |
| Pravastatin Sodium | 24 | $261 |
| Clonazepam | 18 | $261 |
| Zolpidem Tartrate | 16 | $187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $241 | $16,30712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Floridaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.